Global contract research organisation PPD’s Accelerated Enrollment Solutions (AES) business unit Optimal just-in-time (JIT) has entered into a partnership with Cancer Treatment Centers of America (CTCA).

The collaboration aims to accelerate patient enrolment in oncology clinical trials and improve patient’s access to life-changing treatments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It will also help save time for drug researchers in their pursuit to defeat cancer.

CTCA is a cancer care network of hospitals and outpatient care centres in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa.

Integrating the CTCA managed sites with Optimal JIT approach has enabled cancer patients to enter trials faster and allowed AES clients to reduce the time needed for starting the trial.

The approach was successful in reducing site activation time from a maximum of eight months to a minimum of two weeks.

Data generated by CTCA shows results that exceed traditional sites on the same trials when analysing data currency, query rates, and retention.

PPD Optimal service offerings chief operating officer Krystyna Kowalczyk said: “Our collaboration with CTCA demonstrates how we are changing the paradigm of cancer care.

“Together, we are creating meaningful opportunities for cancer patients to participate in clinical trials and access innovative therapies close to home, allowing them to receive care within the context of their support networks in their own communities.

“Some 30% of the patients we enrol with CTCA are from under-represented populations, which reflect our goal of expanding clinical trial opportunities more broadly. Our goal is to enrol more patients from fewer sites in less time to support important oncology trials.

“Thanks to our JIT methodology, a two-week turnaround for first-patient-in is now possible.”